Share Facebook Twitter LinkedIn Pinterest Email Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication
SL Green projects $1.20-a-share FFO guidance increase, supported by $0.80 from One Vanderbilt accounting change (NYSE:SLG)July 24, 2026